Chemotherapy + Radiation for Soft Tissue Sarcoma
Trial Summary
What is the purpose of this trial?
This trial is testing whether a new drug called pazopanib, when combined with chemotherapy and radiation, works better for patients with a specific type of soft tissue cancer. Pazopanib helps stop cancer cells from growing, while chemotherapy and radiation kill the cells. The goal is to see if this combination can improve treatment outcomes.
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are taking certain medications that affect the liver enzyme CYP3A4, you may need to stop them before joining the trial. It's best to discuss your current medications with the trial team to see if any changes are needed.
What data supports the effectiveness of the treatment for soft tissue sarcoma?
Research shows that doxorubicin, often combined with ifosfamide, is a standard treatment for advanced soft tissue sarcoma, with some studies indicating improved survival rates when used in combination with other drugs. However, these combinations can lead to increased side effects. Radiation therapy is also a common part of treatment, especially in combination with surgery, to help control the disease.12345
Is the combination of chemotherapy and radiation therapy safe for treating soft tissue sarcoma?
Doxorubicin, a common chemotherapy drug used for soft tissue sarcoma, can cause heart-related side effects, known as cardiotoxicity. Ifosfamide, another chemotherapy drug, can cause bladder issues, but these can be managed with a protective agent called mesna. Liposomal doxorubicin, a modified form of doxorubicin, has fewer acute and chronic toxicities, making it potentially safer.36789
What makes the chemotherapy and radiation treatment for soft tissue sarcoma unique?
This treatment combines doxorubicin and radiation therapy, which has shown a synergistic effect, meaning they work better together than alone, leading to a high response rate in patients with advanced soft tissue sarcomas. It is administered on an outpatient basis with low toxicity, making it a promising option for those with advanced stages of the disease.16101112
Research Team
Aaron R Weiss
Principal Investigator
Children's Oncology Group
Eligibility Criteria
This trial is for patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas that can be surgically removed. Eligible participants include those with various types of sarcoma, adequate organ function, and no metastases to the central nervous system. They must be able to swallow tablets, have a life expectancy of at least 3 months, and not have received certain prior treatments.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Induction
Patients receive pazopanib and undergo radiation therapy, with or without chemotherapy, to prepare for surgery
Surgery
Patients undergo surgery to remove the tumor
Continuation
Patients continue to receive pazopanib and possibly additional radiation therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Doxorubicin
- Ifosfamide
- Pazopanib
- Radiation Therapy
Doxorubicin is already approved in United States, European Union, Canada, Japan for the following indications:
- Breast cancer
- Ovarian cancer
- Bladder cancer
- Lymphomas
- Leukemias
- Multiple myeloma
- Kaposi's sarcoma
- Soft tissue sarcomas
- Breast cancer
- Ovarian cancer
- Bladder cancer
- Lymphomas
- Leukemias
- Multiple myeloma
- Kaposi's sarcoma
- Soft tissue sarcomas
- Breast cancer
- Ovarian cancer
- Bladder cancer
- Lymphomas
- Leukemias
- Multiple myeloma
- Kaposi's sarcoma
- Soft tissue sarcomas
- Breast cancer
- Ovarian cancer
- Bladder cancer
- Lymphomas
- Leukemias
- Multiple myeloma
- Kaposi's sarcoma
- Soft tissue sarcomas
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor